Marinus Pharmaceuticals Inc. (MRNS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA Summary
MRNS Chart
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
Marinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Marinus Pharmaceuticals NASDAQ: MRNS is a micro-cap pharmaceutical stock with multiple Wall Street analysts seeing significant upside. Both Oppenheimer and Cantor Fitzgerald recently issued or reiterated massive price targets for the company.
Marinus Pharmaceuticals Inc. (MRNS) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Marinus Pharmaceuticals Inc. Profile
| - Industry | - Sector | Dr. Scott N. Braunstein M.D. CEO | NASDAQ (NMS) Exchange | 56854Q200 CUSIP |
| US Country | 165 Employees | - Last Dividend | 23 Sep 2020 Last Split | 31 Jul 2014 IPO Date |
Overview
Marinus Pharmaceuticals, Inc. is a specialized pharmaceutical company concentrating on the development and commercialization of novel therapeutic offerings for individuals afflicted with rare genetic epilepsies and various seizure disorders. Established in 2003 and based in Radnor, Pennsylvania, the company's mission is to address the unmet medical needs of patients with severe neurological conditions. Marinus Pharmaceuticals has established strategic agreements with notable entities such as Purdue Neuroscience Company, CyDex Pharmaceuticals, Inc., Orion Corporation, and Tenacia Biotechnology (Shanghai) Co., Ltd., aiming to enhance its product development and commercialization capabilities.
Products and Services
- ZTALMY (ganaxolone) Oral Suspension:
This product is a flagship offering from Marinus Pharmaceuticals, specifically designed for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), a rare genetic condition. It is approved for use in both adults and pediatric populations, and is available for administration in various settings, from acute and chronic care facilities to patient self-administration at home. The mechanism of action of ZTALMY involves modulation of GABAA receptors, which play a key role in controlling neuronal excitability and are known targets for their anti-seizure, antidepressant, and anxiolytic effects.
- Ganaxolone Development for Additional Genetic Epilepsy Disorders:
Beyond ZTALMY, Marinus Pharmaceuticals is advancing ganaxolone for the treatment of other genetic epilepsy disorders. These include PCDH19-related epilepsy and tuberous sclerosis complex (TSC), both of which represent areas of significant unmet medical need. The company's efforts to extend the benefits of ganaxolone to these conditions underscores its commitment to leveraging its proprietary technology for broadening its impact on people living with hard-to-treat seizure disorders.
